An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes
Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-10-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1209302/full |
| _version_ | 1827799987844546560 |
|---|---|
| author | Yong Peng Yong Peng Huan Yang Ya-hui Xue Ya-hui Xue Quan Chen Quan Chen Hong Jin Hong Jin Shu Liu Shu Liu Shun-yu Yao Shun-yu Yao Miao-qiao Du Miao-qiao Du |
| author_facet | Yong Peng Yong Peng Huan Yang Ya-hui Xue Ya-hui Xue Quan Chen Quan Chen Hong Jin Hong Jin Shu Liu Shu Liu Shun-yu Yao Shun-yu Yao Miao-qiao Du Miao-qiao Du |
| author_sort | Yong Peng |
| collection | DOAJ |
| description | Stiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities. |
| first_indexed | 2024-03-11T20:00:06Z |
| format | Article |
| id | doaj.art-0bf2314dc2664c0ba0797e667f6226ef |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-03-11T20:00:06Z |
| publishDate | 2023-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-0bf2314dc2664c0ba0797e667f6226ef2023-10-04T08:49:13ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-10-011410.3389/fneur.2023.12093021209302An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomesYong Peng0Yong Peng1Huan Yang2Ya-hui Xue3Ya-hui Xue4Quan Chen5Quan Chen6Hong Jin7Hong Jin8Shu Liu9Shu Liu10Shun-yu Yao11Shun-yu Yao12Miao-qiao Du13Miao-qiao Du14Department of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaDepartment of Neurology, Affiliated First Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, Hunan, ChinaThe Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, ChinaStiff person syndrome (SPS) is a rare central nervous system disorder associated with malignancies. In this review, we retrieved information from PubMed, up until August 2023, using various search terms and their combinations, including SPS, stiff person syndrome spectrum disorders (SPSSDs), paraneoplastic, cancer, and malignant tumor. Data from peer-reviewed journals printed in English were organized to explain the possible relationships between different carcinomas and SPSSD subtypes, as well as related autoantigens. From literature searching, it was revealed that breast cancer was the most prevalent carcinoma linked to SPSSDs, followed by lung cancer and lymphoma. Furthermore, classic SPS was the most common SPSSD subtype, followed by stiff limb syndrome and progressive encephalomyelitis with rigidity and myoclonus. GAD65 was the most common autoantigen in patients with cancer and SPSSDs, followed by amphiphysin and GlyR. Patients with cancer subtypes might have multiple SPSSD subtypes, and conversely, patients with SPSSD subtypes might have multiple carcinoma subtypes. The first aim of this review was to highlight the complex nature of the relationships among cancers, autoantigens, and SPSSDs as new information in this field continues to be generated globally. The adoption of an open-minded approach to updating information on new cancer subtypes, autoantigens, and SPSSDs is recommended to renew our database. The second aim of this review was to discuss SPS animal models, which will help us to understand the mechanisms underlying the pathogenesis of SPS. In future, elucidating the relationship among cancers, autoantigens, and SPSSDs is critical for the early prediction of cancer and discovery of new therapeutic modalities.https://www.frontiersin.org/articles/10.3389/fneur.2023.1209302/fullstiff person syndrome (SPS)stiff person syndrome spectrum disorders (SPSSDs)paraneoplasticcancermalignantautoantigen |
| spellingShingle | Yong Peng Yong Peng Huan Yang Ya-hui Xue Ya-hui Xue Quan Chen Quan Chen Hong Jin Hong Jin Shu Liu Shu Liu Shun-yu Yao Shun-yu Yao Miao-qiao Du Miao-qiao Du An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes Frontiers in Neurology stiff person syndrome (SPS) stiff person syndrome spectrum disorders (SPSSDs) paraneoplastic cancer malignant autoantigen |
| title | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
| title_full | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
| title_fullStr | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
| title_full_unstemmed | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
| title_short | An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes |
| title_sort | update on malignant tumor related stiff person syndrome spectrum disorders clinical mechanism treatment and outcomes |
| topic | stiff person syndrome (SPS) stiff person syndrome spectrum disorders (SPSSDs) paraneoplastic cancer malignant autoantigen |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1209302/full |
| work_keys_str_mv | AT yongpeng anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yongpeng anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT huanyang anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yahuixue anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yahuixue anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT quanchen anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT quanchen anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT hongjin anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT hongjin anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shuliu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shuliu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shunyuyao anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shunyuyao anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT miaoqiaodu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT miaoqiaodu anupdateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yongpeng updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yongpeng updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT huanyang updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yahuixue updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT yahuixue updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT quanchen updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT quanchen updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT hongjin updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT hongjin updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shuliu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shuliu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shunyuyao updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT shunyuyao updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT miaoqiaodu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes AT miaoqiaodu updateonmalignanttumorrelatedstiffpersonsyndromespectrumdisordersclinicalmechanismtreatmentandoutcomes |